• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Novel approach to MS therapeutics: anti-CD40L

June 21, 2023  

CLINICAL CASES IN MS – A case of worsening mobility during the pandemic

June 13, 2023  

Re-evaluating the balance of efficacy and safety with disease-modifying therapies

June 8, 2023  

Selected highlights from CMSC 2023

June 6, 2023  

NfL – a guide to use in MS practice

May 31, 2023  

AAN update on anti-CD20 agents: long-term data

May 10, 2023  

Emerging role of CHI3L1 as MS biomarker

May 2, 2023  

sNfL a biomarker of future disease activity: APLIOS

April 12, 2023  

Is vitamin D supplementation justified?

April 5, 2023  

CLINICAL CASES IN MS – A YOUNG WOMAN WITH BREAKTHROUGH DISEASE ON FINGOLIMOD

March 29, 2023  
Previous
9
10
11
12
13
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Revised recommendations on the differential diagnosis of MS posted on July 25, 2023
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions